ACADIA Pharmaceuticals Inc (ACAD)
16.18
-0.09
(-0.55%)
USD |
NASDAQ |
Nov 21, 16:00
16.20
+0.02
(+0.09%)
After-Hours: 20:00
ACADIA Pharmaceuticals Enterprise Value: 2.127B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 2.127B |
| November 20, 2024 | 2.142B |
| November 19, 2024 | 2.132B |
| November 18, 2024 | 2.268B |
| November 15, 2024 | 2.225B |
| November 14, 2024 | 2.267B |
| November 13, 2024 | 2.362B |
| November 12, 2024 | 2.418B |
| November 11, 2024 | 2.475B |
| November 08, 2024 | 2.373B |
| November 07, 2024 | 2.297B |
| November 06, 2024 | 2.062B |
| November 05, 2024 | 1.931B |
| November 04, 2024 | 1.867B |
| November 01, 2024 | 1.899B |
| October 31, 2024 | 1.862B |
| October 30, 2024 | 1.892B |
| October 29, 2024 | 1.887B |
| October 28, 2024 | 1.887B |
| October 25, 2024 | 1.820B |
| October 24, 2024 | 1.843B |
| October 23, 2024 | 1.812B |
| October 22, 2024 | 1.850B |
| October 21, 2024 | 1.890B |
| October 18, 2024 | 1.980B |
| Date | Value |
|---|---|
| October 17, 2024 | 1.958B |
| October 16, 2024 | 1.937B |
| October 15, 2024 | 1.915B |
| October 14, 2024 | 1.928B |
| October 11, 2024 | 1.917B |
| October 10, 2024 | 1.855B |
| October 09, 2024 | 1.862B |
| October 08, 2024 | 1.840B |
| October 07, 2024 | 1.885B |
| October 04, 2024 | 1.947B |
| October 03, 2024 | 1.883B |
| October 02, 2024 | 1.952B |
| October 01, 2024 | 1.980B |
| September 30, 2024 | 1.993B |
| September 27, 2024 | 2.102B |
| September 26, 2024 | 2.067B |
| September 25, 2024 | 2.040B |
| September 24, 2024 | 2.127B |
| September 23, 2024 | 2.201B |
| September 20, 2024 | 2.241B |
| September 19, 2024 | 2.223B |
| September 18, 2024 | 2.208B |
| September 17, 2024 | 2.196B |
| September 16, 2024 | 2.176B |
| September 13, 2024 | 2.206B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.654B
Minimum
Jun 21 2022
8.384B
Maximum
Dec 01 2020
3.807B
Average
3.206B
Median
Jul 14 2021
Enterprise Value Benchmarks
| Bristol-Myers Squibb Co | 159.82B |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
| Theriva Biologics Inc | -12.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 32.76M |
| Revenue (Quarterly) | 250.40M |
| Total Expenses (Quarterly) | 218.76M |
| EPS Diluted (Quarterly) | 0.20 |
| Gross Profit Margin (Quarterly) | 92.47% |
| Profit Margin (Quarterly) | 13.08% |
| Earnings Yield | 4.82% |
| Operating Earnings Yield | 4.18% |
| Normalized Earnings Yield | 4.821 |